
Shionogi expands rare disease portfolio with IntraBio buyout
Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion. The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio. Aqneursa was approved by the FDA in September 2024… Read More
